Zastumotide - GlaxoSmithKline
Alternative Names: Astuprotimut-R; D1/3 MAGE-3 fusion protein; D1/3 MAGE-3 fusion protein SB MAGE-3; D1/3 MAGE-3 His; D1/3 MAGE-3 His fusion protein; GSK 1572932A; GSK 2132231A; GSK 249553; GSK1203486A; MAGE-A3; MAGE-A3 antigen specific cancer immunotherapeutic; MAGE-A3 ASCI; NSC 719274; SB 249553; SB MAGE-3; SID 534984Latest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; Ludwig Institute for Cancer Research
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; MAGEA 3 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bladder cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer
Most Recent Events
- 14 Apr 2021 Discontinued - Phase-II for Malignant melanoma (Combination therapy, Inoperable/Unresectable) in USA (IM) (GSK website, April 2021)
- 14 Apr 2021 Discontinued - Phase-II for Malignant melanoma (Combination therapy, Metastatic disease) in France, Belgium (IM) (GSK website, April 2021)
- 14 Apr 2021 Discontinued - Phase-II for Malignant melanoma (Inoperable/Unresectable) in Russia, Belgium, France, USA, Finland, Germany, Spain, Poland, Italy, Ireland (IM) (GSK website, April 2021)